| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimat...
Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX))) ("Calliditas") today announced that the European Co...
alliditas Therapeutics AB (NASDAQ:CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM t...
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in des...
Citigroup analyst Yigal Nochomovitz downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Neutral and announces $39 p...
Jefferies analyst Maury Raycroft downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowers the price targ...
